Suppr超能文献

牛磺酸对巴氯芬肠道吸收的相互作用:使用微分方程描述动力学抑制模型的非线性数学处理

Interaction of taurine on baclofen intestinal absorption: a nonlinear mathematical treatment using differential equations to describe kinetic inhibition models.

作者信息

Moll-Navarro M J, Merino M, Casabó V G, Nácher A, Polache A

机构信息

Department of Pharmaceutics, Faculty of Pharmacy, University of Valencia, Burjassot, Spain.

出版信息

J Pharm Sci. 1996 Nov;85(11):1248-54. doi: 10.1021/js9504346.

Abstract

Previous studies showed that the in situ absorption of baclofen in rat jejunum was inhibited by beta-alanine, a nonessential amino acid, and therefore mediated, at least in part, by some beta-amino acid carrier. In this paper a similar study was undertaken using taurine, a sulfonic beta-amino acid, in order to evaluate its effect and to establish a general inhibition model. To achieve this goal, remaining concentrations of inhibitor were also measured and incorporated into the model. Previously, kinetic absorption in situ parameters for taurine in free solution were obtained: Vm = 27.73 +/- 9.99 mM h-1, K(m) = 8.06 +/- 2.82 mM, Ka (passive difussion component) = 0.40 +/- 0.28 h-1. Isotonic solutions containing 0.5 mM baclofen with starting taurine concentrations ranging from 0 to 100 mM were perfused in rat jejunum, and the remaining concentrations of both compounds were measured. The apparent rate pseudoconstant of the drug clearly decreased as the remaining taurine concentration increased. The interaction can be described as a complete competitive inhibition plus a second component, K, noninhibited, K = 0.58 (+/- 0.03) h-1, Ki = 20.62 (+/- 4.04) mM, Vmi = 28.12 (+/- 6.12) mM h-1, Kmi = 11.71 (+/- 2.53) mM, Kai = 0.47 (+/- 0.10) h-1. A residual absorption of baclofen in the presence of high taurine concentrations was observed, which should be attributed to another transport system not associated with the taurine carrier. In order to elucidate whether or not taurine and beta-alanine carriers are two separate entities that baclofen can use for absorption, further experiments using beta-alanine and taurine together as inhibitors (baclofen, 0.5 mM; beta-alanine, 50 mM, and taurine, 50 mM) were developed. Results indicated that baclofen and both amino acids share the same carrier in the intestinal absorption process. We have completed studies using leucine, taurine, and GABA together as inhibitors of drug absorption. An isotonic perfusion solution of 0.5 mM baclofen in the presence of 50 mM leucine, 25 mM taurine, and 25 mM GABA was perfused. Under these conditions the absorption rate pseudoconstant of baclofen decreases until 0.080 h-1 (+/- 0.069). Practical implications of these phenomena are briefly discussed.

摘要

先前的研究表明,大鼠空肠中巴氯芬的原位吸收受到β-丙氨酸(一种非必需氨基酸)的抑制,因此至少部分是由某种β-氨基酸载体介导的。在本文中,使用牛磺酸(一种磺酸β-氨基酸)进行了类似的研究,以评估其作用并建立一个通用的抑制模型。为了实现这一目标,还测量了抑制剂的剩余浓度并将其纳入模型。此前,已获得牛磺酸在游离溶液中的原位动力学吸收参数:Vm = 27.73 +/- 9.99 mM h-1,K(m) = 8.06 +/- 2.82 mM,Ka(被动扩散成分) = 0.40 +/- 0.28 h-1。将含有0.5 mM巴氯芬且起始牛磺酸浓度范围为0至100 mM的等渗溶液灌注到大鼠空肠中,并测量两种化合物的剩余浓度。随着剩余牛磺酸浓度的增加,药物的表观速率假常数明显降低。这种相互作用可以描述为完全竞争性抑制加上第二个成分K,即非抑制成分,K = 0.58(+/- 0.03)h-1,Ki = 20.62(+/- 4.04)mM,Vmi = 28.12(+/- 6.12)mM h-1,Kmi = 11.71(+/- 2.53)mM,Kai = 0.47(+/- 0.10)h-1。在高牛磺酸浓度存在下观察到巴氯芬的残余吸收,这应归因于与牛磺酸载体无关的另一种转运系统。为了阐明牛磺酸和β-丙氨酸载体是否是巴氯芬可用于吸收的两个独立实体,开展了进一步的实验,将β-丙氨酸和牛磺酸一起用作抑制剂(巴氯芬,0.5 mM;β-丙氨酸,50 mM,牛磺酸,50 mM)。结果表明,在肠道吸收过程中,巴氯芬与这两种氨基酸共享相同的载体。我们已经完成了使用亮氨酸、牛磺酸和γ-氨基丁酸一起作为药物吸收抑制剂的研究。将含有0.5 mM巴氯芬且存在50 mM亮氨酸、25 mM牛磺酸和25 mMγ-氨基丁酸的等渗灌注溶液进行灌注。在这些条件下,巴氯芬的吸收速率假常数降至0.080 h-1(+/- 0.069)。简要讨论了这些现象的实际意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验